Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY
JGH Open Pub Date : 2024-09-18 DOI:10.1002/jgh3.70029
Eric Kalo, Scott Read, Asma Baig, Kate Marshall, Wai-See Ma, Helen Crowther, Cameron Gofton, Kate D Lynch, Siddharth Sood, Jacinta Holmes, John Lubel, Alan Wigg, Geoff McCaughan, Stuart K Roberts, Paolo Caraceni, Golo Ahlenstiel, Avik Majumdar
{"title":"Efficacy of albumin use in decompensated cirrhosis and real-world adoption in Australia","authors":"Eric Kalo,&nbsp;Scott Read,&nbsp;Asma Baig,&nbsp;Kate Marshall,&nbsp;Wai-See Ma,&nbsp;Helen Crowther,&nbsp;Cameron Gofton,&nbsp;Kate D Lynch,&nbsp;Siddharth Sood,&nbsp;Jacinta Holmes,&nbsp;John Lubel,&nbsp;Alan Wigg,&nbsp;Geoff McCaughan,&nbsp;Stuart K Roberts,&nbsp;Paolo Caraceni,&nbsp;Golo Ahlenstiel,&nbsp;Avik Majumdar","doi":"10.1002/jgh3.70029","DOIUrl":null,"url":null,"abstract":"<p>The current treatment approach to patients with liver cirrhosis relies on the individual management of complications. Consequently, there is an unmet need for an overall therapeutic strategy for primary and secondary prevention of complications. The clinical potential of long-term albumin infusions supported by recent clinical trials has expanded its indications and holds promise to transform the management and secondary prevention of cirrhosis-related complications. This renewed interest in albumin comes with inherent controversies, compounding challenges and pressing need for rigorous evaluation of its clinical potential to capitalize on its therapeutic breakthroughs. Australia is among a few countries worldwide to adopt outpatient human albumin infusion. Here, we summarize currently available evidence of the potential benefits of human albumin for the management of multiple liver cirrhosis-related complications and discuss key challenges for wide application of long-term albumin administration strategy in Australian clinical practice. Australian Gastroenterological week (AGW), organised by the Gastroenterological Society of Australia (GESA), was held between 9-11 September 2022. A panel of hepatologists, advanced liver nurses and one haematologist, were invited to a roundtable meeting to discuss the use of long-term albumin infusions for liver cirrhosis. management in Australia. In this review, we summarise the proceedings of this meeting in context of the current literature.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"8 9","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70029","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The current treatment approach to patients with liver cirrhosis relies on the individual management of complications. Consequently, there is an unmet need for an overall therapeutic strategy for primary and secondary prevention of complications. The clinical potential of long-term albumin infusions supported by recent clinical trials has expanded its indications and holds promise to transform the management and secondary prevention of cirrhosis-related complications. This renewed interest in albumin comes with inherent controversies, compounding challenges and pressing need for rigorous evaluation of its clinical potential to capitalize on its therapeutic breakthroughs. Australia is among a few countries worldwide to adopt outpatient human albumin infusion. Here, we summarize currently available evidence of the potential benefits of human albumin for the management of multiple liver cirrhosis-related complications and discuss key challenges for wide application of long-term albumin administration strategy in Australian clinical practice. Australian Gastroenterological week (AGW), organised by the Gastroenterological Society of Australia (GESA), was held between 9-11 September 2022. A panel of hepatologists, advanced liver nurses and one haematologist, were invited to a roundtable meeting to discuss the use of long-term albumin infusions for liver cirrhosis. management in Australia. In this review, we summarise the proceedings of this meeting in context of the current literature.

Abstract Image

澳大利亚肝硬化失代偿期使用白蛋白的疗效和实际应用情况
目前对肝硬化患者的治疗方法主要依赖于对并发症的个体化治疗。因此,对一级和二级预防并发症的整体治疗策略的需求尚未得到满足。最近的临床试验证实了长期输注白蛋白的临床潜力,扩大了其适应症,有望改变肝硬化相关并发症的治疗和二级预防。人们对白蛋白的重新关注伴随着固有的争议、复杂的挑战,迫切需要对其临床潜力进行严格评估,以实现治疗上的突破。澳大利亚是世界上少数几个采用门诊输注人血白蛋白的国家之一。在此,我们总结了目前可用的人血白蛋白在治疗多种肝硬化相关并发症方面潜在益处的证据,并讨论了在澳大利亚临床实践中广泛应用长期白蛋白给药策略所面临的主要挑战。澳大利亚胃肠病周(AGW)由澳大利亚胃肠病学会(GESA)主办,于2022年9月9日至11日举行。一个由肝病专家、高级肝病护士和一名血液病专家组成的小组应邀参加了一次圆桌会议,讨论长期输注白蛋白治疗肝硬化的问题。在本综述中,我们将结合当前的文献资料总结此次会议的讨论情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JGH Open
JGH Open GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.40
自引率
0.00%
发文量
143
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信